P2Y12 platelet inhibition in clinical practice

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Thrombosis Research

Background:

• Atherothrombosis, particularly intracoronary, is a primary cause of acute coronary syndrome (ACS) and complications following percutaneous coronary intervention (PCI).
• Platelet activation, adhesion, and aggregation are central to thrombotic processes, making their inhibition vital for managing ACS and post-PCI events.
• The P2Y12 receptor, activated by adenosine diphosphate (ADP), is a key mediator in platelet activation, leading to glycoprotein IIb/IIIa receptor activation and sustained aggregation.

Purpose of the Study:

• To review the pharmacological limitations of the P2Y12 inhibitor clopidogrel.
• To describe newer P2Y12 inhibitors, prasugrel and ticagrelor.
• To discuss the clinical implications of these novel antiplatelet agents.

Main Methods:

• Literature review of pharmacological data and clinical trial outcomes.
• Analysis of P2Y12 receptor antagonism and its downstream effects on platelet function.
• Comparative assessment of clopidogrel, prasugrel, and ticagrelor efficacy and safety profiles.

Main Results:

• Clopidogrel exhibits pharmacological limitations impacting its antiplatelet efficacy.
• Prasugrel and ticagrelor offer alternative P2Y12 inhibition with potentially improved clinical outcomes.
• Introduction of these newer agents has significant implications for managing patients with atherothrombotic disease.

Conclusions:

• Novel P2Y12 inhibitors provide valuable therapeutic options beyond clopidogrel for patients with ACS and those undergoing PCI.
• Understanding the pharmacodynamics and clinical benefits of prasugrel and ticagrelor is essential for optimizing antiplatelet therapy.
• Further research continues to refine the role of P2Y12 inhibitors in cardiovascular disease management.